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The early and accurate differential diagnosis of parkinsonian disorders is still a significant challenge for clinicians. In recent years,
a number of studies have used magnetic resonance imaging data combined with machine learning and statistical classifiers to suc-
cessfully differentiate between different forms of Parkinsonism. However, several questions and methodological issues remain, to
minimize bias and artefact-driven classification. In this study, we compared different approaches for feature selection, as well as dif-
ferent magnetic resonance imaging modalities, with well-matched patient groups and tightly controlling for data quality issues
related to patient motion. Our sample was drawn from a cohort of 69 healthy controls, and patients with idiopathic Parkinson’s
disease (n¼35), progressive supranuclear palsy Richardson’s syndrome (n¼52) and corticobasal syndrome (n¼36). Participants
underwent standardized T1-weighted and diffusion-weighted magnetic resonance imaging. Strict data quality control and group
matching reduced the control and patient numbers to 43, 32, 33 and 26, respectively. We compared two different methods for fea-
ture selection and dimensionality reduction: whole-brain principal components analysis, and an anatomical region-of-interest based
approach. In both cases, support vector machines were used to construct a statistical model for pairwise classification of healthy
controls and patients. The accuracy of each model was estimated using a leave-two-out cross-validation approach, as well as an in-
dependent validation using a different set of subjects. Our cross-validation results suggest that using principal components analysis
for feature extraction provides higher classification accuracies when compared to a region-of-interest based approach. However,
the differences between the two feature extraction methods were significantly reduced when an independent sample was used for
validation, suggesting that the principal components analysis approach may be more vulnerable to overfitting with cross-validation.
Both T1-weighted and diffusion magnetic resonance imaging data could be used to successfully differentiate between subject
groups, with neither modality outperforming the other across all pairwise comparisons in the cross-validation analysis. However,
features obtained from diffusion magnetic resonance imaging data resulted in significantly higher classification accuracies when an
independent validation cohort was used. Overall, our results support the use of statistical classification approaches for differential
diagnosis of parkinsonian disorders. However, classification accuracy can be affected by group size, age, sex and movement arte-
facts. With appropriate controls and out-of-sample cross validation, diagnostic biomarker evaluation including magnetic resonance
imaging based classifiers may be an important adjunct to clinical evaluation.
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¼ Statistical Parametric Mapping, version 12; SVM ¼ support vector machines; T1w ¼ T1 weighted; TBSS ¼ tract based spatial sta-
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Introduction
The early and accurate differentiation of parkinsonian
disorders poses a challenge for clinicians and trialists,
which will become critical with the advent of disease
modifying therapies (van Eimeren et al., 2019). Early
symptoms and signs often overlap between idiopathic
Parkinson’s disease, progressive supranuclear palsy (PSP)
and corticobasal syndrome (CBS, and its pathological
counterpart corticobasal degeneration, CBD). Parkinson’s
disease is the most common form of parkinsonism, with
approximately 140 cases per 100 000 (Porter et al.,
2006) whereas PSP and CBS are each approximately 3
per 100 000 (Coyle-Gilchrist et al., 2016). Misdiagnosis
of PSP and CBS is common, often as Parkinson’s disease,
taking on average nearly 3 years from initial symptoms
to diagnosis, while many cases remain undiagnosed.
There is a pressing need for reliable biomarkers to dif-
ferentiate these disorders, not only to aid diagnosis in
early cases, but to monitor progression in trials and to
support ante mortem studies of pathogenesis (van
Eimeren et al., 2019). Biomarkers should be objective
and observer-independent, reproducible, informative
about the underlying biology and ideally non-invasive.
Candidate biomarkers for parkinsonian disorders have
included cognitive tests (Pillon et al., 1995; Aarsland,
2003; Rittman et al., 2013) and assays of cerebrospinal
fluid, serum or urine such as neurofilament light chain
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(Jabbari et al., 2017; Constantinescu et al., 2019; Jabbari
et al., 2020), supplementing those clinical features that
have high clinicopathological correlations (Alexander
et al., 2014; Respondek et al., 2017; Gazzina et al.,
2019).
Magnetic resonance imaging (MRI) provides a set of
potential biomarkers (Whitwell et al., 2017), with the
advantages of being non-invasive, widely available and
versatile. Multiple MRI methods have the potential to in-
form about the underlying neural systems and the
changes resulting from specific pathologies. Pathognomic
radiological signs have been reported, such as the ‘mickey
mouse’ and ‘hummingbird’ signs of mid-brain atrophy in
PSP, but although they have good specificity, sensitivity is
limited, especially in early stage disease when there would
be most to gain from disease modifying therapies.
Automated methods have been developed using volu-
metric or intensity change in grey matter (GM), for ex-
ample voxel-based morphometry (VBM). Most VBM
studies of grey matter in degenerative parkinsonian syn-
dromes have compared patients to healthy controls
(Brenneis et al., 2004; Cordato et al., 2005; Summerfield
et al., 2005; Beyer et al., 2006; Ghosh et al., 2012;
Yarnall et al., 2014). A few have compared patient groups
against each other (Price et al., 2004; Boxer et al., 2006),
or compared subgroups within each disorder, according
to cognitive impairment (Paviour et al., 2006; Mak et al.,
2015) or neuropsychiatric symptoms (Ghosh et al., 2012;
Yao et al., 2014). White matter (WM) changes have also
been described, using VBM or diffusion tensor imaging
(DTI) measures such as the fractional anisotropy (FA)
and mean diffusivity (MD). Differences are observed for
Parkinson’s disease versus controls (Yoshikawa et al.,
2004; Zhang et al., 2011; Rae et al., 2012; Goveas
et al., 2015), Parkinson’s disease versus PSP (Seppi et al.,
2003) and Parkinson’s disease versus CBS (Boelmans
et al., 2010). A meta-analysis of 43 DTI studies in par-
kinsonian syndromes (Cochrane and Ebmeier, 2013) sug-
gested the potential of diffusion-weighted imaging to
improve the differential diagnosis of parkinsonism.
However, accuracy was often not greater than clinical
criteria, sample sizes were often small, and the utility for
single subject decision-making was limited.
We propose that better classification can be achieved
by using statistical classifiers such as support vector
machines (SVM). Mulitvariate data features from a train-
ing set of data (subjects) can be used to build a model to
classify a new dataset (one or more new subjects). In
addition to individual subject classification, these methods
can identify which features underlie the classification (i.e.
indicative of relevant pathological features) and indices of
confidence or typicality that could be used to assess pro-
gression. Statistical classifiers have been applied to several
neurological and psychiatric disorders, including schizo-
phrenia (Caan et al., 2006; Ingalhalikar et al., 2010),
Alzheimer’s disease, frontotemporal dementia (Davatzikos
et al., 2008) and autism spectrum disorder (Ingalhalikar
et al., 2010, 2011; Bloy et al., 2011). Haller et al. (2012)
used DTI data from 17 Parkinson’s disease patients and
23 patients with ‘atypical parkinsonism’ (including typical
PSP and multiple system atrophy). Using tract based spa-
tial statistics (TBSS), a non-linear SVM algorithm, and a
10-fold cross-validation, classification between
Parkinson’s disease and other patients was accurate
(97.5 6 7.5%, depending on the number of features used
for model training). In combination with manual regions-
of-interest selection, classification accuracies >95% were
also achieved by Prodoehl et al. (2013) in binary differ-
entiation of Parkinson’s disease and PSP. T1-weighted
MRI can also support binary classification >85% (Focke
et al., 2011; Salvatore et al., 2014).
Unfortunately, whilst previous studies have demon-
strated successful differential diagnosis of parkinsonism,
significant limitations and methodological questions re-
main. First, many studies have used poorly matched
groups in terms of age or clinical variables, and different
numbers of subjects in each group. The latter is of par-
ticular concern because commonly used statistical classi-
fiers which minimize the classification error (including
SVMs), are liable to inflate accuracy from unbalanced
datasets (see for example, He and Garcia, 2009; Tang
et al., 2009).
A second problem relates to the selection of features
for the classifier. For example, previous studies have used
either mean values from specified regions or individual
voxel data, including manual selection with operator de-
pendence. In addition, studies have rarely compared dif-
ferent MRI modalities to assess whether T1-weighted or
diffusion-weighted imaging (DWI) are most useful. While
most studies using T1-weighted data have used GM vol-
ume as feature type, cortical thickness is a valuable alter-
native (for example Gao et al., 2018; Wilson et al.,
2019).
A third problem concerns the validation of results,
which is challenging with small group sizes. Most studies
have included small numbers of subjects, and therefore
employed cross-validation techniques. However, the use
of the same subjects for training and validation is contro-
versial and may inflate classification accuracies. A more
conservative approach is to split the data in two inde-
pendently acquired groups: one for training and the other
for validation (Salvatore et al., 2014), or to use inde-
pendent datasets for validation.
Finally, most studies have failed to consider how differ-
ent levels of motion during the MRI acquisition affect
classification accuracies. This issue is particularly import-
ant when working with patients with movement disor-
ders. Head motion results in artefacts and smoothing of
MRI data. Different levels of motion across groups could
significantly contribute to classifier’s apparent success in
separating patient groups.
In the present study, we aimed to address these four
methodological issues in the context of differential diag-
nosis of Parkinson’s disease, CBS and the Richardson’s
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syndrome variant of PSP (PSP-RS). Specifically, we com-
pare three equal-sized and closely matched groups of
patients; we used automatic feature selection of grey and
white matter signals; and we undertook an initial leave-
two-out cross-validation followed by validation in an in-
dependent data set. The comparison of well-matched
groups, with automatic feature selection is a challenge for
imaging markers, but one that is necessary to develop un-
biased and useful clinical research tools.
Methods
Subjects
Our analysis sample was drawn from a cohort of 69
healthy controls (mean age 67.3 years, range 51–84), 35
people with idiopathic Parkinson’s disease (mean age
66.9 years, range 46–76, UK Parkinson’s disease brain
bank criteria), 52 people with probable PSP-RS [mean
age 71.9 years, range 51–92, MDS clinical diagnostic cri-
teria for PSP-Richardson’s syndrome (Höglinger et al.,
2017)] and 36 people with probable CBS [mean age
66.9 years, range 39–88 (Armstrong et al., 2013)], with
UPDRS-III motor subscale for all patients.
For the cross-validation analysis (see below), 19 cases
per group were selected so as to match for age, sex, and
MRI motion, with similar UPDRS-III scores in the patient
groups. Local Ethical Committee approval and written
informed consent were obtained. All participants had
mental capacity to consent under UK law.
MRI data acquisition
Diffusion and T1-weighted MRI data were acquired for
all subjects using a 3 T Siemens Tim TRIO scanner at the
Wolfson Brain Imaging Centre. Diffusion MRI data were
acquired with a twice refocused spin echo (TRSE) se-
quence (Reese et al., 2003). Diffusion sensitising gradients
were applied along 63 non-collinear directions with a b-
value of 1000 s/mm2, together with one acquisition with-
out diffusion weighting (b¼ 0). The remaining imaging
parameters were: TR¼ 7800 ms, TE¼ 90ms,
matrix¼ 96 96, field of view (FoV)¼192 192 mm,
slice thickness¼ 2 mm without gap, interleaved slice ac-
quisition, and the PAT mode was GRAPPA with an ac-
celeration factor of 2. A high resolution 3D T1-weighted
MPRAGE image was also acquired (TR¼ 2300 ms,
TE¼ 2.98 ms, FoV¼ 256 240 mm, matrix¼ 256 256,
slice thickness¼ 1 mm).
Quality assurance and exclusion
criteria
MRI data in general, and diffusion MRI in particular,
can suffer from significant distortions in the presence of
head motion. Given the motor deficits associated with
parkinsonism, metrics of motion are especially important
to ensure the quality of the data across control and pa-
tient groups. Estimating the amount of motion in 3D
MPRAGE images is not trivial. We used SPM12 (www.
fil.ion.ucl.ac.uk/spm/) to estimate the level of smoothness
associated with the MPRAGE images of each subject.
Because of its induction of spatially correlated noise, mo-
tion is expected to correlate with the inherent smoothness
in the data. Firstly, we performed full image segmentation
using the Segment tool in SPM12 (Ashburner and
Friston, 2005). Secondly, the spm_estimate_smoothness
function was used to estimate the inherent smoothness
associated with soft tissue outside the brain, cerebral spi-
nal fluid (CSF) and bone. This function returns a spatial
smoothness estimator based on the variances of the nor-
malized spatial derivatives as described in (Kiebel et al.,
1999). The estimated smoothness values were then com-
pared across controls and patients, and significant out-
liers (>2 standard deviations from the mean) were
visually inspected and removed from further analysis
(data quality was evidently poor for all subjects flagged
by this metric).
For the diffusion MRI data, we estimated motion arte-
facts in two ways. Firstly, we used the eddy_correct func-
tion in FSL v5.0.9 (www.fmrib.ox.ac.uk/fsl) to perform
affine registration between each diffusion weighted volume
and the b¼ 0 image. The output log files from eddy_cor-
rect were used to estimate the absolute displacement
between each diffusion MRI volume and the b¼ 0 images,
as well as the relative displacement between a given vol-
ume and its predecessor. Significant outliers (>2 standard
deviations from the mean) on either metric were identified
and removed from further analysis. Subjects were also
excluded if they moved more than 3 mm (1.5  voxel size)
between any two diffusion MRI volumes. Secondly, we
used an automated method for detection of striping pat-
terns in the data (Neto-Henriques et al., 2016). Striping
artefacts are caused by spin history and are a common
consequence of head motion when interleaved MRI acquisi-
tions are used. Subjects with more than five volumes
affected by striping artefacts were excluded.
Cross-validation and validation
groups
The remaining subjects were divided into two subgroups:
a cross-validation group and an independent validation
group. The subjects included in the cross-validation group
were selected to satisfy the following criteria:
• Equal numbers of subjects across the four control/pa-
tient groups
• No significant differences in motion metrics across the
four control/patient groups
• No significant age or sex differences across the four
control/patient groups
• UPDRS-III scores matched for all three patient groups
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All remaining subjects who had not been excluded by
the motion quality control metrics made up the validation
group.
Pre-processing of MRI data
The T1-weighted MPRAGE images were segmented and
normalized into MNI space using SPM12. Firstly, the
MPRAGE images were segmented into grey and white
matter maps using Segment (Ashburner and Friston,
2005). For this step, six tissues types were considered
(grey matter, white matter, CSF, bone, soft tissue outside
the brain, and air and other signals outside the head).
Total intracranial volume (TIV) was estimated by sum-
ming probability maps for GM, WM and CSF in native
space. Segmentation was then followed by DARTEL
(Diffeomorphic Anatomical Registration Through
Exponentiated Lie Algebra) (Ashburner, 2007), an algo-
rithm which increases the accuracy of inter-subjects align-
ment by modelling the shape of each brain using three
parameters per voxel, and generating an increasingly
sharp average template over several iterations. Finally,
the sixth iteration of the DARTEL template was used to
generate spatially normalized and Jacobian scaled grey
matter images in MNI space (Mechelli et al., 2005;
Ashburner, 2009).
In parallel, T1-weighted data were pre-processed using
freesurfer version 6.0.0 (surfer.nmr.mgh.harvard.edu).
Cortical reconstruction, volumetric segmentation and cor-
tical thickness extraction used recon-all, and the output
was inspected for quality assurance. The individual cor-
tical thickness (CT) maps were then transformed into
MNI space using the non-linear mapping method pro-
posed by Wu et al. (2018).
The diffusion MRI data were skull-stripped and motion
corrected using FSL v5.0.9, and the diffusion tensor
model fitted using a non-linear fitting algorithm imple-
mented in C and matlab. Fractional anisotropy (FA) and
mean diffusivity (MD) were computed for each subject.
FA and MD maps were transformed onto a common
template space using DTI-TK, a tensor-based registration
approach (Zhang et al., 2006, 2007a) and a study-specif-
ic population-based atlas (Zhang et al., 2007b).
Feature extraction
For the GM volume and cortical thickness maps, feature
extraction was performed in two ways: (i) using the
cortical and subcortical regions-of-interest from the
Harvard-Oxford Atlas (neuro.imm.dtu.dk/wiki/Harvard-
Oxford_Atlas) and (ii) using principal component analysis
(PCA).
For the region-of-interest analysis, 63 grey matter cor-
tical and subcortical ROIs were applied to the spatially
normalized GM maps for each subject, and the average
GM volume value per ROI calculated, hence generating
63 independent features per subject (Fig. 1A). For the
PCA analysis, a GM mask was first created by threshold-
ing the mean GM map obtained from DARTEL in MNI
space (threshold P¼ 0.1). This mask was applied to the
images from each subject, and the voxels contained with-
in the mask were included in a multi-subject PCA ana-
lysis, resulting in N  1 independent features, where N
represents the number of subjects included in this analysis
(Fig. 1B). Analogous procedures were applied to cortical
thickness maps, excluding subcortical ROIs, resulting in
48 cortical-thickness features per subject.
ROI and PCA methods for feature extraction were also
applied to the FA and MD maps. For the ROI approach,
100 white matter regions from the EVE atlas (http://
lbam.med.jhmi.edu/) were used to extract the average FA
and MD values for each region and subject (Fig. 1C).
For PCA, a white matter mask was first generated by
thresholding the FA map corresponding to the study-spe-
cific template (threshold FA 0.2). Voxels selected from
the FA and MD maps of all subjects were included to
generate N  1 independent features (Fig. 1D).
Statistical analysis
The subjects included in the cross-validation and inde-
pendent validation groups were tested for differences in
age, UPDRS-III score, MMSE score, TIV and motion
metrics using ANOVA, Welch’s ANOVA or Kruskal–
Wallis ANOVA depending on whether the relevant
assumptions were met for each metric. The assumption
of normality was assessed using the following criteria:
skewness and kurtosis of residuals between 2 and 2
(George and Mallery, 2010), ShapiroWilk test for nor-
mality and normal QQ-plots. Homogeneity of variance
was accepted if the ratio of the largest residual variance
estimate to the smallest group residual variance estimate
does not exceed 3 (Dean and Voss, 1999). Analysis of
sex differences across groups was performed using Chi-
squared testing.
Feature ranking and statistical
classification
Four parallel streams of subsequent analysis were per-
formed, one for each data type and feature extraction
method combination: (i) GM maps þ ROIs, (ii) GM
maps þ PCA, (C) diffusion maps þ ROIs, and (D) diffu-
sion maps þ PCA. Following feature extraction, each fea-
ture was individually normalized using its mean and
standard deviation (z-scoring). The normalized features
generated by each feature extraction approach were then
ranked separately, using the Fisher Discriminant Ratio
(FDR):
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Figure 1 Data analysis pipelines. Analysis pipelines for each combination of data type and feature extraction method. (A) T1-weighted MRI
and ROIs. (B) T1-weighted MRI and PCA. (C) Diffusion MRI and ROIs. (D) Diffusion MRI and PCA.
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where li and r
2
i denote the mean and the variance of the
ith class, respectively.
The top feature for each stream was used in combination
with support vector machines (SVMs) to construct a statis-
tical model for pairwise classification of healthy controls,
Parkinson’s disease, CBS and PSP-RS. The remaining fea-
tures were added to the model, one at a time, in the order
of their FDR ranking, and the classification accuracy of
each model as a function of the number of features was
calculated. The SVM analysis was performed using the
LIBSVM package in matlab (Chang and Lin, 2011).
To assess the accuracy of the four analysis streams, we
first used leave-n-out cross-validation. The N available
subjects are randomly split into a training set of size (N
 n) and a test set of size n. The N-n training set is used
to build a model, whose performance is tested on the n
test set. In this study, n¼ 2 for the pairwise comparisons,
with the testing set including one subject from each
group. Multiple rounds of cross-validation are performed
for different permutations of the subjects left out of the
training set. We report the average classification accuracy
across all iterations of the cross-validation. However, this
method may inflate classification accuracies. Therefore
the leave-two-out cross-validation was supplemented by
an independent validation using a different set of cases
altogether. For the cross-validation approach, feature
ranking using FDR was recalculated for each fold using
the subjects in the training subgroup only, and the same
ranking applied to the two subjects left out. For the inde-
pendent validation, the FDR ranking was determined
using the cross-validation group, and the ranking order
applied to the independent group.
To facilitate comparison between MRI modalities and
feature extraction methods, all feature selection used FDR
ranking. We report classification accuracies as a function
of the number of ranked features included in the model.
Optimal feature selection for each pairwise comparison
(group), MRI modality (T1w, DWI) and method (ROI,
PCA) might use different numbers of features for each
combination. Therefore, we present the accuracies (range,
mean and maximum) obtained across the range of fea-
tures in the classification model. The progressive inclusion
of ranked features leads to non-independent observations
(the first k features are also included in kþ 1 features),
so we do not use serial null hypothesis testing of differen-
ces between combinations of methods. Instead, we report
the range of classification accuracies obtained with each
combination of methodologies.
Spatial localization of the most
relevant features
To illustrate the most relevant features that support the
SVM classifications between groups (19 controls, 19
Parkinson’s disease, 19 CBS and 19 PSP-RS), we present
a map of the SVM weighting for each feature. The par-
ameter weights for each pairwise group-comparison were
rescaled so that the most useful feature for each compari-
son has a normalized weight of 1. We present GM
regions from the Harvard-Oxford Atlas to show the most
relevant brain features for group discrimination. A similar
process was repeated for white matter ROIs in the EVE
Atlas, where each ROI was assigned a weight for its FA
value and a weight for its MD value. The rescaling was
performed for FA and MD features together, so that the
top diffusion feature has weight of 1.
Data availability
Participant consent prevents open data access but aca-
demic (non-commercial) requests for data sharing would
be welcome. Please contact the senior author. The princi-
pal software used (SPM, FSL, LIBSVM and matlab) are
publicly available.
Results
Quality assurance and subject
exclusion
Examples of MRI images for the subjects excluded by the
motion quality control assessment are shown in
Supplementary material, Section A. Exclusion criteria
reduced the sample size to 62 controls (7 subjects
excluded by DWI motion metrics), 32 Parkinson’s disease
(1 subject excluded by DWI motion metrics, 2 subjects
excluded by both DWI and MPRAGE metrics), 33 PSP-
RS (16 subjects excluded by DWI motion metrics, 3 sub-
jects excluded by both DWI and MPRAGE metrics) and
26 CBS (6 subjects excluded by DWI motion metrics, 4
subjects excluded by both DWI and MPRAGE metrics).
Cross-validation and validation
groups
After quality assurance, patient groups were confirmed to
be matched for motion metrics, total intracranial volume
(TIV), age and sex (Table 1). The 62 controls were
younger than the patients, and included a larger propor-
tion of females. We therefore randomly removed females
and younger subjects to reach a sample of 43 age- and
sex-matched healthy controls.
For the cross-validation group, 19 patients were
selected with each diagnosis, matching demographics and
UPDRS-III, with 19 controls matched for motion metrics,
age and sex. The remaining 58 subjects (24 controls, 13
Parkinson’s disease, 14 PSP-RS and 7 CBS) formed the
independent validation test cohort.
Table 1 shows the demographic and neuropsychological
evaluation scores for all groups. For the cross-validation
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group, there was no significant difference by diagnosis in
sex, age or UPDRS-III score. There was a significant dif-
ference in MMSE score across the different groups: post
hoc tests revealed that both PSP-RS and CBS patients
had a lower MMSE compared to healthy controls and
Parkinson’s disease patients. Motion metrics were
matched across groups. For the independent validation
group age and head motion were matched across groups,
but there were mild differences between PSP-RS and con-
trols or CBS in terms of age or smoothness respectively
(see Table 1). A summary of the motion metrics for data-
sets excluded after quality control are presented in
Supplementary material, Section C.
Comparison between GM volume
and cortical thickness
Figure 2 shows the classification results using GM vol-
ume or cortical thickness. The methods performed simi-
larly when cross-validation is used with PCA features
(Fig. 2A). However, using ROI features, cortical thick-
ness underperforms relative to GM volume, for all pair-
wise comparisons (Fig. 2C). The reverse is observed
for the independent validation results where classifica-
tion accuracies are lower for GM volume features, for
all pairwise comparisons (Fig. 2B and D). The perform-
ances of different ROI atlases for thickness feature ex-
traction are presented in Supplementary material,
Section D. Since the results of GM volume and thick-
ness are similar, we focus the remaining analyses on
GM volume features as used in most previous classifica-
tion studies.
Cross-validation results
Cross-validation classification results are presented in
Table 2, for both GM volume and diffusion data. The
mean and maximum accuracies and IQR were calculated
over the number of features used (ROIs or PCA compo-
nents). The accuracy results for group comparisons are
Figure 2 GM volume versus cortical thickness. Comparison between GM volume (blue) and cortical thickness (orange) as feature types.
The range of classification accuracies presented for each pairwise comparison and combination of methodological variables corresponds to the
results obtained as different numbers of features are included in the statistical model. (A) Cross-validation results when PCA is used for feature
extraction. (B) Independent validation results when PCA is used for feature extraction. (C) Cross-validation results when ROIs are used for
feature extraction. (D) Independent validation results when ROIs are used for feature extraction.
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all above chance (50%), but some are lower than previ-
ous reports from unmatched studies (e.g. Haller et al.,
2012; Salvatore et al., 2014). With the well-matched
groups described in our study, mean classification accura-
cies were in the range 62.16–90.3% for T1-weighted
data and 61.26–94.95% for diffusion data.
Plots showing classification accuracy, sensitivity and
specificity as a function of the number of features
included in the model (number of ROIs or PCA compo-
nents) can be found in Supplementary material, Section
E. Comparisons between controls and PSP-RS and be-
tween Parkinson’s disease and PSP-RS are shown as rep-
resentative examples.
Independent validation results
Table 3 summarizes the results using independent valid-
ation samples to test model accuracy, for both GM vol-
ume and diffusion data. The mean and maximum
accuracies and IQR were calculated over the number of
features used (ROIs or PCA components). Training and
testing in less well-matched independent sets of subjects
resulted in mean classification accuracies in the range
44.37–71.87% for T1-weighted data and 57.63–90.49%
for diffusion data.
Plots showing classification accuracy, sensitivity and
specificity as a function of the number of features
included in the model (number of ROIs or PCA principal
components) can be found in Supplementary material,
Section F. Comparisons between controls and PSP-RS





Figure 3 shows the classification accuracies for each
method of feature extraction, across all pairwise group
comparisons, for cross-validation and independent valid-
ation. Note the comparison between data reduction meth-
ods (PCA green, ROI yellow) and feature types (GM
volume top row, FAþMD bottom row), for within sam-
ple cross-validation (left) and out-of-sample independent
validation (right).
Table 2 Classification accuracies achieved for pairwise comparisons using a leave-two-out cross-validation approach
Mean accuracy (%) IQR (%) Max accuracy (%)
T1-weighted data (GM volume maps)
GM maps þ ROIs
C vs PD 71.96 2.18 85.46
C vs CBS 83.36 0.59 91.69
C vs PSP-RS 73.74 5.68 81.02
PD vs CBS 77.93 3.88 85.87
PD vs PSP-RS 67.44 2.35 70.91
PSP vs CBS 62.16 0.55 65.65
GM maps þ PCA
C vs PD 82.54 15.17 97.78
C vs CBS 90.33 8.00 99.31
C vs PSP-RS 84.60 10.77 95.84
PD vs CBS 87.31 9.28 97.09
PD vs PSP-RS 87.38 13.50 96.95
PSP vs CBS 88.23 16.17 100.0
Diffusion MRI data (FA and MD maps)
FA and MD maps þ ROIs
C vs PD 61.26 12.88 75.21
C vs CBS 70.13 5.54 77.28
C vs PSP-RS 82.44 6.44 87.53
PD vs CBS 72.89 10.66 81.99
PD vs PSP-RS 74.93 6.58 85.04
PSP vs CBS 79.84 7.89 90.72
FA and MD maps þ PCA
C vs PD 85.43 19.43 99.72
C vs CBS 90.06 9.90 97.37
C vs PSP-RS 92.51 10.15 99.86
PD vs CBS 84.40 7.34 91.55
PD vs PSP-RS 89.49 3.98 96.40
PSP vs CBS 94.95 12.67 100.0
For each pairwise comparison, two patients, one from each group, were left out of the training phase for each cross-validation fold and used to estimate model accuracy. The classi-
fication accuracies presented correspond to the mean and maximum accuracies obtained when different numbers of features (ROIs or PCA components) are included in the statis-
tical model. Inter-quartile range (IQR) is also shown.















Only qualitative descriptions are used to compare be-
tween the two methods for model validation (see
Methods section). Figure 4 shows box plots for the range
of classification accuracies obtained with each approach,
across all pairwise comparisons, for both types of feature
extraction (ROIs and PCA components).
Spatial localization of the most
relevant features
Figure 5A indicates the relative importance of each GM
ROI for classification (the model used for independent val-
idation). Figure 5B shows the analogous maps of diffusion
features. These are the most relevant regional features for
the classification accuracies summarized in Table 3.
Discussion
This study addresses four key issues in the use of MRI
for diagnostic or classification biomarkers for
parkinsonian disorders. We show that even with well-
matched groups, of equal size, and tight control of mo-
tion artefacts, one can achieve accurate cross-validated
differential diagnosis of Parkinson’s disease, PSP-RS and
CBS. The strongest results were achieved when principal
components analysis was used for feature extraction,
resulting in consistent mean accuracies above 80% and
maximum accuracies over 90% for all group compari-
sons, using either diffusion or grey matter volume data.
The use of PCA feature extraction gave higher accuracies
than ROIs, with a difference of approximately 25%.
While mapping the distribution of pathology was not an
aim of the present study, the regions that were most con-
tributory to the support vector machine classifiers were
biologically plausible, including the basal ganglia. Using
diffusion weighted images for classification, the highly
ranked features included diffuse FA and MD signals, and
neither metric outperformed the other (FA versus MD).
Overall, we confirmed that good diagnostic accuracy
can be achieved using either grey or white matter features
from standard structural and diffusion MRI sequences,
respectively. The classifications by diffusion and GM vol-
ume data were generally similar for the cross-validation
group (‘within-sample’). However, there were some
Table 3 Classification accuracies achieved using the independent validation group
Mean accuracy (%) IQR (%) Max accuracy (%)
T1-weighted data (GM volume maps)
GM maps þ ROIs
C vs PD 47.75 8.11 64.86
C vs CBS 63.95 6.45 74.19
C vs PSP-RS 62.78 4.61 76.32
PD vs CBS 47.14 8.75 60.00
PD vs PSP-RS 57.67 3.70 62.96
PSP vs CBS 44.37 4.76 61.90
GM maps þ PCA
C vs PD 55.66 5.41 67.57
C vs CBS 63.12 3.23 67.74
C vs PSP-RS 68.99 3.29 76.32
PD vs CBS 50.95 10.00 60.00
PD vs PSP-RS 71.87 4.63 81.48
PSP vs CBS 48.52 4.76 57.14
Diffusion MRI data (FA and MD maps)
FA and MD maps þ ROIs
C vs PD 59.74 5.41 75.68
C vs CBS 78.74 5.37 87.09
C vs PSP-RS 90.49 2.63 94.74
PD vs CBS 77.90 15.00 85.00
PD vs PSP-RS 86.78 3.70 92.59
PSP vs CBS 76.33 4.76 80.95
FA and MD maps þ PCA
C vs PD 57.63 10.81 72.97
C vs CBS 73.41 6.45 80.64
C vs PSP-RS 80.87 5.92 89.44
PD vs CBS 80.81 5.00 85.00
PD vs PSP-RS 81.48 3.70 88.89
PSP vs CBS 80.82 4.95 90.63
Seventy subjects (19 from each group) were used to train the model, and validation was performed on 58 unseen patients and controls. The classification accuracies presented cor-
respond to the mean and maximum accuracies obtained when different numbers of features are included in the statistical model (ROIs or PCA components). Inter-quartile range
(IQR) is also shown.
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notable differences. For example, diffusion data resulted
in better differentiation than volume data between PSP-
RS and CBS patients (80% versus 62%), but poorer dif-
ferentiation between controls and Parkinson’s disease
(61% versus 72%). Neither data type outperformed the
other in all cases, although diffusion data produced
higher accuracies when comparing PSP-RS patients to
controls or CBS patients. With the independent validation
groups, accuracy generally decreased (by an average
13%), despite less stringent matching. This decrease may
indicate overestimation by within-sample cross-validation.
However, the difference was less marked when diffusion
metrics were used (5% average reduction in accuracy)
than GM volumes (average 23% reduction in accuracy,
some to chance levels). Using a principal components
analysis over grey matter volume of white matter diffu-
sion signals provides higher classification accuracies com-
pared to a set of anatomical regions-of-interest when
cross-validation is used to estimate accuracy, but lower
classification accuracies in the independent validation
analysis.
The selection of imaging features is critical to the per-
formance and interpretation of classifiers. MRI provides
a rich repertoire of structural, functional, neurochemical
and diffusion features. We focus on the T1-weighted and
diffusion tensor images which are most widely available,
with short sequences that are readily tolerated by
patients, and which require minimal operator expertise.
These would be an advantage for scalable multisite stud-
ies, or in support of diagnostics and stratification in a
trial context. Nonetheless, even these standard sequences
provide many potential features and feature extraction
options.
We compared two approaches for feature extraction,
based on (i) a priori regions of interest from a common
anatomical atlas and (ii) a data-driven principal compo-
nents analysis. When PCA was used for feature extrac-
tion, accuracy, sensitivity and specificity generally
Figure 3 PCA versus ROIs. Comparison between feature extraction methods: PCA (green) and ROIs (yellow). The range of classification
accuracies presented for each pairwise comparison and combination of methodological variables corresponds to the results obtained as different
numbers of features are included in the statistical model. (A) Cross-validation results when GM volume maps are used as feature type. (B)
Independent validation results when GM volume maps are used as feature type. (C) Cross-validation results when FA and MD maps are used as
feature type. (D) Independent validation results when FA and MD maps are used as feature type.
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increase as more features are added to the model until
a plateau at 15 components for GM volume data and
15-30 for diffusion data (see the plots in Supplementary
material, Section E). The plateau is generally sustained
until the last 2–5 features are added, consistent with
previous studies (Salvatore et al., 2014). This is
expected for PCA with FDR feature-ranking, which
concentrate predictive information in the earlier fea-
tures. When ROIs are used as features, only the FDR
criterion is used for feature ranking and the ranking of
features may differ for each fold of the cross-validation.
The non-predictive information remains more evenly
distributed across ROI features than PCA features. The
advantage of PCA could be due to small localized
changes in brain morphology and/or function that are
averaged across a ROI. On the other hand, the differen-
ces between the two feature extraction methods are sig-
nificantly reduced when an independent sample is used
for validation. This suggests that the PCA approach
may be more vulnerable to the overfitting with cross-
validation approaches.
We also compared two types of tissue signal—GM vol-
ume and thickness measures based on a T1-weighted se-
quence, and metrics of white matter tissue organisation
using diffusion tensor imaging. We replicated previous
studies in that both types of data support classification
above chance. Neither type clearly outperforms the other
across all pairwise comparisons among our three clinical
cross-validation groups. However, features obtained from
diffusion MRI data resulted in higher classification accu-
racies using the independent validation cohort (for both
ROIs and PCA feature extraction). For some key con-
trasts of interest (Parkinson’s disease versus CBS, and
Parkinson’s disease versus PSP-RS) the classification ac-
curacy in the independent sample using diffusion data
was as good as the cross-validation results. Despite the
Figure 4 Cross-validation versus independent validation. Comparison between cross-validation (magenta) and independent validation
(blue) results. The range of classification accuracies presented for each pairwise comparison and combination of methodological variables
corresponds to the results obtained as different numbers of features are included in the statistical model. (A) Results obtained when PCA is
used for feature extraction, with GM volumes maps as feature type. (B) Results obtained when ROIs are used for feature extraction, with GM
volumes maps as feature type. (C) Results obtained when PCA is used for feature extraction, with FA and MD maps as feature type. (B) Results
obtained when ROIs are used for feature extraction, with FA and MD maps as feature type.
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improvement of thickness over volume in the independent
validation, diffusion metrics still outperformed GM thick-
ness for three out of the six groupwise comparisons
(Supplementary material, Section G). In the main results,
we combined FA and MD features for the classifier, al-
though single diffusion metrics [i.e. FA-only or MD-only
were not consistently inferior (Supplementary material,
Section H)]. Interestingly, the combination of diffusion
and GM volume features did not increase classification
accuracy with FDR feature ranking (Supplementary ma-
terial, Section I).
Close matching by demographics, clinical severity and
motion artefacts is essential to properly evaluate and
compare candidate biomarkers. Without such matching,
the apparent success of some previous imaging-based bio-
markers in distinguishing clinical groups may have been
inflated by individual differences that are unrelated to the
structural and neuropathological consequences of disease.
Figure 5 Spatial localization of top classification features. Colour-coded images showing the relative importance of each ROI for
pairwise classification using SVM. The top ranked feature for each pairwise group comparison has a normalized weight of 1 and is shown in
yellow, while the least important features are shown in red. (A) Cortical and sub-cortical ROIs used for classification with GM volume features.
(B) White matter ROIs used for classification with FA and MD features. The top row shows the spatial distribution of the most relevant FA
features, while the bottom row shows the localization of the most relevant MD features.
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For example, in unselected cases, motion artefacts were
greater in patients than controls: 26% of patients
exceeded our motion criteria compared to only 10% of
controls. Exclusion rates varied by group: 9% of
Parkinson’s disease, 28% of CBS and 37% of PSP-RS.
Machine learning tools such as support vector machines
are very sensitive to systematic patterns in the data but
are agnostic as to the origins of such patterns e.g. motion
versus neuropathology versus atrophy. The very high
classification accuracies between patient groups reported
in some previous studies (up to 100%), may be inflated
by differential motion. The effects of head motion in
MRI data analysis are well documented. For example,
head motion during acquisition of 3D T1-weighted MRI
images reduces grey matter volume estimates (Reuter
et al., 2015), while head motion in a diffusion MRI ac-
quisition can create spurious group differences (Yendiki
et al., 2014). Similarly, the comparison of groups at dif-
ferent stages of disease, or different levels of severity,
may confound classification. Unfortunately, there is no
universal severity or staging rating scale across parkinson-
ian disorders, with disease-specific features in the UPDRS
and PSP-rating-scale. The forthcoming PSP functional rat-
ing scale and new CBS functional rating scale may be ap-
plicable across groups, but we applied the available
UPDRS-III with its focus on common motor features
across our three clinical groups.
Despite matching by age, sex, motion artefacts, and
having similar UPDRS-III scores, the issue of differential
disease severity remains challenging, from two perspec-
tives. First, there is currently no single rating scale or in-
vestigation that fully summarizes disease severity across
Parkinson’s disease, PSP and CBS, either as a clinical
scale, neurotransmitter or functional brain image. Even
where a clinical scale such as UPDRS is applicable across
the disorders, it may not give a like-for-like index of dis-
ease stage (e.g. from onset to death) or functional decline
(e.g. activities of daily living), or pathology (e.g. dopa-
mine depletion, or cell loss). Second, the three diseases
may each have prolonged prodromal phases and long
periods in which patients are misdiagnosed. PSP and
CBD typically take 2–3 years from symptoms to diagnosis
(Coyle-Gilchrist et al., 2016; Mamarabadi et al., 2018),
while Parkinson’s disease causes under-recognized clinical
manifestations like constipation and REM-sleep behav-
ioural disorder many years before tremor and akinesia. It
is too soon to know whether MRI based classification is
capable of differentiating these disorders in early pro-
dromal stages, or pre-symptomatically, in the way that
has been shown for frontotemporal dementia (Rohrer
et al., 2015). For PSP, the recent operationalization of
early stage ‘oligosymptomatic’ and ‘possible’ cases will
enable MRI biomarkers of PSP to be tested earlier
(Höglinger et al., 2017).
Phenotypic variation other than severity is also chal-
lenging. The classical Richardson’s syndrome presentation
of PSP has very high clinico-pathological correlations to
PSP-pathology. However, this classical phenotype may
represent a minority of presentations of PSP-pathology:
cognitive, linguistic and behavioural presentations are
common (Respondek et al., 2014; Höglinger et al.,
2017). Similarly, CBS has many phenotypic variants, with
motoric, behavioural and language presentations
(Armstrong et al., 2013). This study does not include
cases from the full phenotypic range of corticobasal syn-
dromes, or syndromes caused by corticobasal degener-
ation (Alexander et al., 2014). The current study was not
designed to resolve the issue of heterogeneity, but rather
to highlight methodological considerations, and best prac-
tice, which we hope can be carried forward to identify
robust biomarkers of a wide range of phenotypic expres-
sions of the pathologies of Parkinson’s disease, PSP and
corticobasal degeneration (Jabbari et al., 2020).
Although we have addressed four key methodological
issues, several limitations remain. This was a single centre
study, resulting in a modest sample size when compared
to recent multi-centre studies (Huppertz et al., 2016;
Nigro et al., 2017; Jabbari et al., 2020). This limits the
generalisation of our results to different clinical sites with
potentially different scanning practices, scanner manufac-
turers and sequence parameters. Our diffusion data were
not corrected for EPI distortions, as data were acquired
before reverse-phase encode direction acquisitions was
common practice. Therefore, the FA and MD maps used
for classification were affected by distortion artefacts, al-
beit in all groups. The control and patient groups
included in this study were matched for age, sex, motion
parameters and UPDRS-III scores (for the patients).
However, there was a difference in MMSE between the
groups; and previous studies have highlighted the cogni-
tive impairments resulting from Parkinson’s disease
(Williams-Gray et al., 2013), PSP (Rittman et al., 2013)
and CBS (Burrell et al., 2014). Given the correlations be-
tween cognitive function and structural and diffusion
MRI in Parkinson’s disease, PSP-Richardson’s syndrome,
and CBS (Paviour et al., 2006; Ghosh et al., 2012; Rae
et al., 2012; Mak et al., 2015) the non-matching by cog-
nitive dysfunction could contribute to classification.
Against this argument, is that different cognitive deficits
are hallmarks of Parkinson’s disease, PSP and CBS, and
to match a cognitive profile would compromise the repre-
sentativeness of the patients chosen. Another potential
limitation of this study is that patient labels were
assigned using clinical diagnostic criteria not histopath-
ology, and the limitation of clinicopathological correla-
tions may cap the statistical classifier’s ability to learn
and separate the different patterns of disease. Our
centre’s diagnostic accuracy of CBS and PSP-RS is in line
with other centres (Alexander et al., 2014; Gazzina et al.,
2019), with generally high clinicopathological correlation
of PSP-Richardson’s syndrome (>90%) relative to CBS/
CBD (>60%). Finally, all our data were subjected to
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strict data quality control criteria, with the aim that the
disease patterns detected by SVM were independent of
the severity of motion present in those data. While this
ensures that poor data quality will not be mistaken for
real effects of the pathology, it may also exclude patients
with symptoms that do not allow them to be still enough
to undergo the MRI examination. For example, 19 sub-
jects with PSP-RS (37% of the original sample) were
excluded by our quality control criteria, which may bias
the sample in the PSP-RS group. This indicates a trade-
off, whereby high-quality data cohorts may not be repre-
sentative of the full range of disease.
In summary, we suggest that machine learning meth-
ods for MRI data can be used to aid the automatic dif-
ferential diagnosis of PSP-RS, CBS and Parkinson’s
disease, meeting critical criteria set by the Movement
Disorder Society Neuroimaging Study Group and the
JPND Working group ASAP-SYn-Tau (van Eimeren
et al., 2019). However, to make such a contribution,
and augment clinical assessments, these techniques must
guard against methodological biases from different lev-
els of motion across patient groups, and poorly
matched samples. With closely matched groups, of
equal size and similar severity, the use of diffusion
weighted images is particularly encouraging, in its high
accuracy rate and generalization to independent data.
Application of these methods to large samples and mul-
tisite studies will be facilitated by international collab-
orative studies of early stage or atypical presentations
of each disease [e.g. PROSPECT-UK (Woodside et al.,
2017) and the Four-repeat tauopathy neuroimaging ini-
tiative], aiming for reliable, unbiased, disseminated tools
for early differential diagnosis and stratification in clin-
ical trials of new therapies.
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Supplementary material is available at Brain
Communications online.
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Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang
AE; for the Movement Disorder Society-endorsed PSP Study Group,
et al. Clinical diagnosis of progressive supranuclear palsy: the move-
ment disorder society criteria. Mov Disord 2017; 32: 853–64.
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